title: Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
abstract: The use of neoadjuvant systemic therapy for the treatment of breast cancer patients is increasing. Pathologic response in the form of pathologic complete response (pCR) and grading systems of partial response, such as the residual cancer burden (RCB) system, gives valuable prognostic information for patients and is used as a primary endpoint in clinical trials. The breast cancer and pathology communities are responding with efforts to standardize pathology in patients receiving neoadjuvant chemotherapy. In this review, we summarize the challenges that postneoadjuvant systemic therapy surgical specimens pose and how pathologists and the multidisciplinary team can work together to optimize handling of these specimens. Multidisciplinary communication is essential. A single, standardized approach to macroscopic and microscopic pathologic examination makes it possible to provide reliable response information. This approach employs a map of tissue sections to correlate clinical, gross, microscopic, and imaging findings in order to report the presence of pCR (ypT0 ypN0 and ypT0/is ypN0) versus residual disease, the ypT and ypN stage using the current AJCC/UICC staging system, and the RCB.
authors.affiliation: Department of Pathology, Yale University, New Haven, CT, USA. veerle.bossuyt@yale.edu.
authors.forename: Veerle
authors.initials: V
authors.lastname: Bossuyt
authors.affiliation: The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: W Fraser
authors.initials: WF
authors.lastname: Symmans
mesh_terms: D018906:Antineoplastic Agents, Alkylating; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D033183:Interdisciplinary Communication; D020360:Neoadjuvant Therapy; D018365:Neoplasm, Residual; D010336:Pathology / Q000379:methods* / Q000592:standards; D013048:Specimen Handling / Q000379:methods* / Q000592:standards; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating